Transneural
Transneural Therapeutics is a preclinical-stage biotechnology company developing AI-engineered neuroplastogen small molecules for neuropsychiatric and neurodegenerative diseases, with lead candidate TN-001 targeting treatment-resistant major depressive disorder and PTSD.
- Company typePrivate
- Founded2025
- HeadquartersIssaquah, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Transneural does
Transneural Therapeutics, Inc. is a preclinical-stage biotechnology company developing a focused pipeline of novel small-molecule neuroplastogens intended to treat neuropsychiatric and neurodegenerative diseases. The company's core technology combines AI-engineered chemical scaffold design with applied medicinal chemistry to produce tailored receptor engagement at serotonin G-protein coupled receptors, specifically a dual 5-HT2A partial agonist and 5-HT2B antagonist profile. Lead candidate TN-001 is engineered to induce rapid structural neuroplasticity and synaptogenesis without hallucinogenic or dissociative effects and with a cardiac safety profile that supports chronic daily dosing. The pipeline consists of TN-001 and two additional undisclosed small-molecule programs, with initial indications targeting major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) and broader expansion into other neuropsychiatric and neurodegenerative conditions with high unmet need. Transneural was founded in April 2025 as a spin-out of CaaMTech, a pharmaceutical drug discovery company focused on psychedelic-inspired medicines, and is headquartered in Issaquah, Washington under Delaware corporate law.
The company's business model is pharmaceutical drug development and eventual commercialization of prescription therapeutics, with future revenue dependent on FDA approval and downstream licensing or sale of approved products. Transneural has no commercial products, no pricing model, and no disclosed funding rounds; revenue is expected to follow traditional pharmaceutical development pathways, including potential milestone-based partnerships or licensing transactions once candidates reach clinical milestones. The go-to-market approach leverages deep CNS pharmaceutical expertise from leadership, including CEO Charmaine Lykins, who executed ten product launches across Karuna Therapeutics, MapLight Therapeutics, Acadia Pharmaceuticals, Lundbeck, Sunovion, and Eli Lilly, and Chief R&D Officer Mark A. Demitrack, MD, who led the NDA submission for duloxetine (Cymbalta) at Lilly and the clinical development of NeuroStar TMS at Neuronetics. Target patient segments are the approximately 21 million people in the United States with MDD and 13 million with PTSD, with a particular focus on the 30–50% of depressed patients and approximately 33% of PTSD patients who are treatment resistant to current therapies.
Transneural firmographics
Firmographics- Name
- Transneural
- Legal name
- Transneural Therapeutics, Inc.
- Website
- https://transneural.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Transneural Therapeutics is a preclinical-stage biotechnology company developing AI-engineered neuroplastogen small molecules for neuropsychiatric and neurodegenerative diseases, with lead candidate TN-001 targeting treatment-resistant major depressive disorder and PTSD.
- Ownership category
- akta.pro rank
Transneural industry classification
Industry- Product category
- CNS Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Transneural is headquartered
LocationHeadquarters
- HQ city
- Issaquah
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Transneural business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Drug Development and Commercialization: Transneural is a preclinical-stage biotechnology company. Revenue will be generated through the development and commercialization of novel neuroplastogen therapeutics. The company is developing a pipeline of small molecule drugs including lead asset TN-001 for MDD and PTSD. As a preclinical biotech, no commercial revenue currently exists.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Transneural product offering
Product offeringCore offering
Transneural is a preclinical-stage biotechnology company developing a focused pipeline of small-molecule neuroplastogens engineered on AI-designed chemical scaffolds to treat neuropsychiatric and neurodegenerative diseases. Lead asset TN-001 is a dual 5-HT2A partial agonist/5-HT2B antagonist designed to induce rapid antidepressant-associated neuroplasticity and synaptogenesis without hallucinogenic or dissociative effects, with a cardiac safety profile enabling chronic daily at-home dosing. The pipeline additionally includes two undisclosed small-molecule programs beyond TN-001.
Product overview
Transneural Therapeutics is a preclinical-stage biotechnology company developing a focused pipeline of novel rapid-acting neuroplastogens for neuropsychiatric and neurodegenerative diseases. The company's portfolio centers on lead asset TN-001, a dual 5-HT2A partial agonist/5-HT2B antagonist engineered on an AI-designed chemical scaffold, plus two additional undisclosed programs. All pipeline assets target G-protein coupled receptors (GPCRs) with tailored serotonergic receptor engagement designed to deliver rapid antidepressant efficacy without hallucinogenic effects. The company emerged from stealth in April 2025 and is progressing toward clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- TN-001 TN-001 is Transneural's lead preclinical asset, a dual 5-HT2A partial agonist/5-HT2B antagonist small-molecule neuroplastogen designed on an AI-engineered chemical scaffold. It induces rapid structural neuroplasticity and synaptogenesis without hallucinogenic or dissociative effects, with a cardiac safety profile enabling chronic daily at-home dosing. It is being developed for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), targeting the substantial treatment-resistant patient population inadequately served by current therapies.
- Pipeline Programs (2 additional programs) Transneural's pipeline includes two additional small-molecule programs beyond lead asset TN-001, focused on novel rapid-acting agents for neuropsychiatric indications. Specific targets and indications for these programs have not yet been publicly disclosed, though all pipeline assets share the company's AI-engineered scaffold approach targeting GPCRs with tailored serotonergic receptor engagement.
Quantifiable outcome
- TN-001 rapidly induces statistically significant and dose-dependent structural neuroplasticity in rat neuronal cell culture assay, shown by increased number of neurons, synapses, and neurite network
- +4 more outcomes
Companies that use Transneural
Customer profileSegments3 records
Ideal customer profiles2 records
Transneural technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Transneural partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CaaMTechfoundationalTransneural is a spin-out of CaaMTech, a pharmaceutical drug discovery company utilizing a collaborative scientific approach to engineer novel small-molecule psychedelic-inspired medicines to treat mental health conditions. CaaMTech's research and discovery capabilities in psychedelic-inspired medicines provided the foundation for Transneural's formation and initial technology platform.
Scale indicators2 records
Recent moves7 records
Expansion highlights4 records
Transneural competitors and assessment
Company assessmentDirect peers
- MapLight Therapeutics: MapLight Therapeutics is a clinical-stage CNS biopharma developing targeted therapies for schizophrenia and other neuropsychiatric disorders, sharing Transneural's CNS focus, mechanistic precision-medicine approach, and prior C-suite leadership (Lykins served as CCO at MapLight).
- GH Research: GH Research is developing mebufotenin, a potent 5-HT2A agonist, for treatment-resistant depression, sharing the same serotonergic neuroplastogen mechanism and MDD focus as Transneural, though pursued via an inhalable psychedelic rather than a non-hallucinogenic oral molecule.
- Compass Pathways: Compass Pathways is developing psilocybin therapy for treatment-resistant depression, a directly overlapping indication and mechanism class (5-HT2A-mediated neuroplasticity) as Transneural's TN-001, positioning both as non-SSRI options for the same patient population.
- Cybin: Cybin is developing deuterated psilocybin analogs and other 5-HT2A-targeting neuroplastogens for MDD and anxiety disorders, sharing Transneural's core thesis that engineered serotonergic molecules can deliver durable antidepressant effects with improved safety/dosing profiles.
- atai Life Sciences: atai Life Sciences is a clinical-stage biopharma building a pipeline of psychedelic and psychedelic-inspired therapies for depression, PTSD, and other mental health conditions, overlapping Transneural's therapeutic area and mechanism rationale (5-HT2A/neuroplasticity) but with a broader, asset-collecting model.
- MindMed: MindMed is developing psychedelic-inspired medicines (e.g., MM-120 for anxiety disorders) targeting 5-HT2A and related CNS receptors, directly comparable to Transneural's strategy of engineering serotonergic neuroplastogens for psychiatric indications.
Broad incumbents
- Johnson & Johnson (Spravato): J&J markets Spravato (esketamine), the only FDA-approved NMDA/5-HT-targeting rapid-acting antidepressant for treatment-resistant depression, representing the incumbent benchmark that Transneural's non-hallucinogenic, daily-dosed TN-001 would compete against if approved.
- Sage Therapeutics: Sage Therapeutics is a CNS-focused biopharma with Zurzuvae (zuranolone) for postpartum depression and other GABAergic modulators in development, comparable as a focused CNS innovator pursuing novel mechanisms for treatment-resistant depression rather than a psychedelic-based approach.
- Karuna Therapeutics (Bristol Myers Squibb): Karuna developed KarXT/COBENFY (xanomeline/trospium), a muscarinic agonist for schizophrenia that was acquired by Bristol Myers Squibb for ~$14B; its leadership alumni (including Transneural CEO Charmaine Lykins) and similar CNS strategy of replacing dopaminergic/serotonergic drugs with targeted receptor modulators make it highly comparable.
Emerging players
- Neumora Therapeutics: Neumora Therapeutics is a clinical-stage neuroscience company developing precision neuropsychiatric therapies including NMRA-140 (a 5-HT2A inverse agonist) for MDD, making it a close peer in target, indication, and emerging-stage profile to Transneural.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Transneural social profiles
Digital presenceTransneural financial estimates
Financial estimateRevenue estimate
Valuation estimate
Transneural leadership team
Management profileNumber of profiles
Profiles3 records
Transneural funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Transneural M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Transneural
What does Transneural do?
Transneural is a preclinical-stage biotechnology company developing a focused pipeline of small-molecule neuroplastogens engineered on AI-designed chemical scaffolds to treat neuropsychiatric and neurodegenerative diseases. Lead asset TN-001 is a dual 5-HT2A partial agonist/5-HT2B antagonist designed to induce rapid antidepressant-associated neuroplasticity and synaptogenesis without hallucinogenic or dissociative effects, with a cardiac safety profile enabling chronic daily at-home dosing. The pipeline additionally includes two undisclosed small-molecule programs beyond TN-001.
Is Transneural a public or private company?
Transneural is a private company. It is classified as venture growth investor backed and is currently operating.
When was Transneural founded?
Transneural was founded in 2025. It employs 1 to 10 people.
Where is Transneural based?
Transneural is headquartered in Issaquah, United States, in the North America region.
How does Transneural make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Who are Transneural's main competitors?
Direct peers on record are MapLight Therapeutics, GH Research, Compass Pathways, Cybin, atai Life Sciences and MindMed. Broad incumbents are Johnson & Johnson (Spravato), Sage Therapeutics and Karuna Therapeutics (Bristol Myers Squibb). Neumora Therapeutics is listed as an emerging player.
Does Transneural have an API?
No public API is recorded for Transneural.
What industry is Transneural in?
Transneural's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy), with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.